Opioid- and Stimulant-related Harms in Canada Published: (December 2020)
This update is based on data submitted to the Public Health Agency of Canada on or before November 10, 2020. Due to differences in identifying and reporting cases, comparisons over time and between provinces and territories should be interpreted with caution. Refer to the technical notes for more information.
|Type of opoids||Percent|
|2020 (Jan to Jun) - Fentanyl - Female - Ontario||22%|
|2020 (Jan to Jun) - Fentanyl - Male - Ontario||78%|
|2020 (Jan to Jun) - Fentanyl analogues - Female - Ontario||14%|
|2020 (Jan to Jun) - Fentanyl analogues - Male - Ontario||86%|
|2020 (Jan to Jun) - Non-fentanyl opioids - Female - Ontario||68%|
|2020 (Jan to Jun) - Non-fentanyl opioids - Male - Ontario||32%|
This update would not be possible without the collaboration and dedication of provincial and territorial (PT) offices of Chief Coroners and Chief Medical Examiners as well as PT public health and health partners and Emergency Medical Services data providers. We would also like to acknowledge the Canadian Institute for Health Information (CIHI) for collecting and providing the data used for reporting opioid-related poisoning hospitalizations.
Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioids and stimulant-related Harms in Canada. Ottawa: Public Health Agency of Canada; December 2020. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants
Learn more about opioids and stimulants in Canada
- Date modified: